Volume 15, Issue 1, Pages 96-105 (January 2014) Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial Fiona Bath-Hextall, PhD, Mara Ozolins, MSc, Sarah J Armstrong, PhD, Graham B Colver, DM, William Perkins, FRCP, Paul S J Miller, PhD, Prof Hywel C Williams, DSc The Lancet Oncology Volume 15, Issue 1, Pages 96-105 (January 2014) DOI: 10.1016/S1470-2045(13)70530-8 Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure Trial profile *Numbers who saw the nurse were not available from some smaller centres; an unknown greater number saw a doctor in clinic before assessment; potential participants were directed to the nurse who explained the study. †Non-acceptance by eligible patients. ‡Because of unsuitable histology, death, poor health, regression of basal-cell carcinoma, participant was no longer available for follow-up or was unable to reach. §Excluded from safety analysis. ¶Not known before treatment. ‖Both not serious. **Electrodesiccation and curettage. The Lancet Oncology 2014 15, 96-105DOI: (10.1016/S1470-2045(13)70530-8) Copyright © 2014 Elsevier Ltd Terms and Conditions